AI with intent: How Inizio is redefining pharma through precision and partnership
October 29, 2025 | Intelligent Commercialization
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the future of Intelligent Commercialization™.
Empowering human insight at Fierce Pharma Week
This year’s Fierce Pharma Week brought together the leading voices shaping the future of pharmaceutical communications, strategy, and innovation. At Inizio, we had a front-row seat through the contributions of experts, who showcased how we’re combining human expertise with AI to deliver precision, credibility, and measurable impact.
Across every discussion our experts took part in, one theme stood out: AI delivers its greatest value when guided by intent. From elevating scientific storytelling to advancing field medical enablement and enabling data-driven decision-making, our teams demonstrated how purposeful integration of AI is transforming how pharma connects, learns, and leads.
Here’s how our experts brought that vision to life at Fierce Pharma Week through connected insight, practical innovation, and partnership that drives real-world change.
Engineering credibility in an AI-powered world
In the session “From earned to engineered,” Inizio Evoke’s Will Reese, Theresa Dolge, and Kelly Cusumano urged pharma communicators to rethink visibility in an AI-shaped world.
They discussed the rise of “thin” versus “thick” content, concise, discoverable insights that feed AI models versus deeply sourced narratives that build authority. The strongest brands balance both, ensuring that what AI learns is accurate, credible, and humanly resonant.
As Will noted, “AI rewards content that’s structured, traceable, and solution-oriented.” The key is designing material that both humans and machines can trust, because what’s visible shapes what’s believed.
Explore the full talk delivered by Inizio Evoke here.
Building real capability with real impact
AI delivers the most value when guided by experts who use it with purpose.
Inizio Medical’s Kelly Malloy, SVP of Customer Engagement for AI and Augmented Intelligence, brought this to life during her talk, “The business case for next-gen field medical enablement,” alongside a panel of industry leaders:
- Tiffanie Stewart, PhD, Senior Director, MSLs, Inizio Engage
- Donnie Wooten, Jr., PharmD, Senior Director, Global Medical Capabilities – Oncology, AstraZeneca
- Michael Kahn, formerly Senior Director, Medical Affairs Operations Leader, Spark Therapeutics
Using tools like MSL Interact, teams can rehearse realistic HCP conversations in a safe, simulated environment. It’s a powerful example of using AI to enhance human skills like empathy, curiosity, and dialogue, rather than aiming to replace them. The panel highlighted the value of adaptive, continuous learning along with a “Four Ps” model: prepare, practice, perform, pivot.
“Generative AI is an accelerant, not a shortcut,” Kelly reminded the audience. “When used deliberately, it bridges science and storytelling- helping field teams communicate more clearly and confidently in the moments that matter most.”
Watch the full talk delivered by Inizio Medical here.
Transforming medical affairs with data and AI
Inizio Advisory’s session, “Precision Medical Affairs in action,” led by Lori Klein, Partner, Medical Affairs Practice Lead, brought together expert insights from:
- Nikheel Kolatkar, VP, US Medical, Genentech
- Loucif Ouyahia, Global Head of Digital Healthcare, Jazz Pharmaceuticals
They described how precision Medical Affairs moves from reactive to predictive by using AI-driven analytics to uncover care gaps, localize insights, and personalize scientific engagement, connecting data across functions to create continuous feedback loops, and equip teams to partner confidently with AI.
As Lori summarized, “When you integrate human and machine intelligence, you don’t just find new insights – you create new impact.”
Watch Inizio Advisory’s Fierce Pharma Week session here.
Precision launch: aligning data, strategy, and purpose
In their second session, “Precision launch: Integrating data and AI to power commercial and medical strategy,” Inizio Advisory’s Jo-Ann Saitta, Partner, Global Data Strategy, and Lori Klein, spotlighted the value of data unity and strategic alignment.
Through centralized, compliant products like ClarityNav, part of the Navigator AI™ pharma teams can align next-best actions, understand the voice of the customer, and orchestrate personalized engagements. When medical and commercial teams operate from a single, trusted source of truth, every insight becomes actionable, and every action measurable.
This is what modern launch excellence looks like: predictive, connected, and powered by purpose.
Watch Inizio Advisory’s second Fierce Pharma Week session here.
Innovation rooted in the human equation
Every session echoed one essential truth: AI is only as valuable as the people guiding it. Whether in content, training, or analytics, Inizio’s approach to innovation is grounded in the belief that technology should elevate human creativity rather than eclipse it.
We’re building systems that help decision-makers within healthcare and pharma:
- See more clearly
- Decide more precisely
- Act with greater purpose
Because empathy, curiosity, and expertise, not algorithms, sustain trust in healthcare.
From insight to impact with Intelligent Commercialization™
Fierce Pharma Week reinforced our mission: to lead the future of Intelligent Commercialization™ – where human insight, data, and AI converge to deliver clarity, speed and measurable impact.
- Through strategic intelligence, Navigator AI™ enables faster, smarter portfolio and investment decisions, sharpens strategy, strengthens field execution, and accelerates launches.
- Through medical intelligence, iON.AI™ converts scientific evidence into actionable insights that enhance the influence and effectiveness of Medical Affairs execution.
- Through commercial intelligence, Cognitev™ translates primary generated behavioral data into activation – fueling omnichannel engagement, optimizing field force strategy, and aligning tactics across the lifecycle.
Together, we help the industry move beyond insight to action through accelerating launches, sharpening strategies, and driving real-world impact across the full lifecycle of commercialization.
Ready to unlock the power of Intelligent Commercialization™ across your organization?
Let’s talk about how using AI with intent can elevate your strategy, accelerate impact, and drive smarter engagement across the product lifecycle. Connect with our experts here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Research Partnership has been ranked in the Pharma Times Pharma Fast 50
Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research...
Women’s health in emerging markets
Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and...
Research Partnership has published a new Living with Lupus (SLE) market report for 2017
SLE is a progressive and debilitating disease which affects 5 million people worldwide.
PEGASUS AND UCL JOIN FORCES IN INSPIRING HEALTHY DECISIONS
Pegasus, an Ashfield company, part of UDG Healthcare plc, is proud to announce the launch of its new propriety model for planning in health – CHANGE – which was developed...
Cool heads in a crisis?
Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics
Biosimilars: Bringing patients into the conversation
Published in eyeforpharma January 2017 by Mariel Metcalfe
Access and elimination: the future of DAAs in hepatitis C
Published in Pharmaphorum January 2017
EphMRA One Day Meeting
We are delighted to be attending and presenting a paper at the EphMRA one day meeting on Tuesday 21st February, in London
Video: Segmentation research
Why would a pharma company want to carry out a segmentation study? What are some of the challenges? Head of Business Analytics Tom Nolte and Associate Director Dr Marianne Jaeger...
Pharmaceutical Market Research Conference 2017
We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 1-2 February in Parsippany, NJ.